George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
Oxford, UK - 1 February, 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announces that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson's Disease. This follows Sio's announcement yesterday about the resignation of their CEO where Sio also indicated a constraint on resource requirements that has caused Sio to deprioritise the programme. All rights shall be returned to Oxford Biomedica at no cost to the Company.
Current status of programme
Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD. In October 2020, Sio announced positive six-month follow up data from the second cohort of the trial, showing a 21-point mean improvement in UPDRS Part III 'OFF' score, a 40% improvement from baseline based on the two evaluable patients in the study. AXO-Lenti-PD continued to be shown to be well-tolerated with no treatment-related serious adverse events at six months. To date, six patients have been dosed in the Phase 2 study. Oxford Biomedica originally out-licensed AXO-Lenti-PD (previously named OXB-102) to Sio Gene Therapies (previously called Axovant Gene Therapies), in June 2018.
Highlights:
· Increase in global (undepleted) Mineral Resource Estimate to over 380,000 oz Au and 6,100,000 oz Ag contained metal*.
· Ore Reserves of 1.10Mt @ 2.38 g/t Au and 43.16g/t Ag for over 80,500 oz Au and 1,400,000 oz Ag, equivalent to approximately three years of production*.
· Resource update represents a c. 19% increase over the previous (2020) undepleted global resource estimate (announced in April 2020) on a gold ounce only basis.
· Over 1.33Mt of ore has been mined from the open pits at Kiziltepe to the end of December 2021, of which approximately 1.03Mt has been processed (quoted as dry tonnes).
Highlights of the Cacharposa maiden Mineral Resource at a 0.16% CuEq [1] cut-off grade:
· Mineral Resource of 396.8Mt @ 0.44% CuEq for 1.40 Mt Cu, and 1.80 Moz Au in the Indicated category.
· Mineral Resource of 96.9 Mt @ 0.37% CuEq for 0.28 Mt Cu, and 0.38 Moz Au in the Inferred category.
I. 96% of consumers who had taken CholBiome®X3 and who had measured their total cholesterol levels reported that their levels had reduced. Of these:-
a. 17% reported reductions in total cholesterol of >30%
b. 50% reported reductions in total cholesterol of between 16-30%
c. 29% reported reductions in total cholesterol of between 1-15%
II. 88% of consumers stated that their LDL-cholesterol (bad cholesterol) had been reduced (with 8% not knowing their LDL cholesterol levels).
III. This level of reduction was sustained with 93% of users who took the product for more than 1 year reporting reduced levels of total and LDL cholesterol.
IV. No consumers taking CholBiome®X3 reported any side effects or tolerance issues.
TRADING AND OPERATIONS UPDATE - 2021 PRODUCTION AT UPPER END OF GUIDANCE AND CAPEX WITHIN GUIDANCE - PRODUCTION AND CAPEX GUIDANCE PROVIDED FOR 2022
SDX Energy Plc (AIM: SDX), the MENA-focused oil and gas company, is pleased to provide an update on its unaudited operating results, capex, cash, and liquidity position for the twelve months ended 31 December 2021 and sets out production and capex guidance for 2022. All monetary values are expressed in United States dollars net to the Company unless otherwise stated.
Mark Reid, CEO of SDX, commented:
"I am pleased to announce that 2021 production was at the higher end of guidance and that capex was within guidance. Our cash management in the year has also been strong, with cash at the year-end growing to US$10.6 million from US$10.1 million last year.
Our full year 2022 production guidance is lower than 2021 actual production of 5,886 boe/d mainly due to the proposed South Disouq disposal announced today and natural depletion across wells at South Disouq. Production in Morocco in 2022 will be lower due to a decision not to immediately renew a five-year customer contract until we have better visibility on future gas supply and gas pricing to support the full term of a new contract. As a result of this decision, we are reducing 2022 Moroccan capex guidance by c.US$6.0 million compared to 2021. Notwithstanding this, we are still planning to drill up to sixteen wells this year but expect overall capex guidance to be lower in 2022 at US$21.5-US$23.0 million."
Why not
Averaged up
Support level strengthening
Can see the buying force to continue on the drop
Overhang getting low